drugset / Trial / NCT03986385
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2020-06-30
- Completion
- 2021-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |